Accolade — Investor Presentation (January 2024)
39 slides from Accolade's investor presentation, January 2024
Slide 1: Accolade Inc. Investor Presentation
January 2024 NASDAQ: ACCD Accolade Inc. Investor Presentation
Slide 2: Forward-looking statements
This presentation contains “forward-looking statements” –that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such ‘‘anticipate,’’ ‘‘b
Slide 3: Building a customer-obsessed, nationwide healthcare delivery company
Building a customer-obsessed, nationwide healthcare delivery company 3 Accolade ©2024 - Confidential
Slide 4: Investment Highlights
Investment Highlights Targeting $1B in revenue and 15-20% Adjusted EBITDA in 5 years Consistent 20% revenue growth with increasing profitability Market leader in highly underpenetrated Personalized Healthcare market High revenue visibility and customer diversification Integrated platform enables sca
Slide 5: What stands us apart
World-class Partner technology platform What stands us apart Broad customer Flywheel profile value 5 Accolade ©2024 - Confidential
Slide 6: High Touch Healthcare Services Powered by Next Gen Technology
High Touch Healthcare Care Nurse Case Women’s Behavioral Health Health Services Powered by Nurses Advocates Managers Nurses Clinician Next Gen Technology Physicians (typically internal medicine or family practice) Panel of 1000+ Physician Our extraordinary care teams drive engagement, Specialists so
Slide 7: The Physician Gap impact is real
Delayed and deferred doctor visits the Physician Gap Fragmented communication impact is real between providers (episodes) Unnecessary surgeries and wrong treatments 7 Accolade ©2024 - Confidential
Slide 8: We put doctors at the heart of the solution
We put doctors at the heart of the solution Physician-led Care Team Internal Physicians & Therapists Elite Specialists Expert Nurses Care Advocates Doctor-to-doctor Support Targeted outreach Single Point of Entry data sharing Benefits Verification of benefits ID card Claims and appeals Utilization m
Slide 9: Accolade fixes the Physician Gap
80% of visits occur same day Accolade fixes Data sharing with the Physician Gap outside physicians visit summaries and relevant data Overall savings: 4%+ EMO: 25% of surgeries cancelled, 85% care plans improved 9 Accolade ©2024 - Confidential
Slide 10: Trust and human connection, every time
Trust and human connection, every time Member fingerprint Specific care team matching Integrated point True Health Actions solutions and care pathways 10 Accolade ©2024 - Confidential
Slide 11: Our World-Class Technology
Member Call Our Fingerprint Scheduling World-Class Technology Skills-Based Routing Automation We use technology and data to seamlessly give members trust and human connection, every time. TrueHealth AI Actions 11 Accolade ©2024 - Confidential
Slide 12: The future state is connected for ease
The future state is connected for ease Specialists Front door engagement Meds Pre-existing burdens Therapy SDOH Primary Care Benefits Point Solutions Lack of combined data timely Telehealth is used to form care High-risk member True Health Actions Urgent Actionable steps Care are given to member in
Slide 13: True Health Actions Drive Personalized Care Experience
True Health Actions A Drive Personalized Care Experience B A Concept – Member Health Snapshot B Deployed – Alerts C C Deployed – True Health Action Recommendations 13 Accolade ©2024 - Confidential
Slide 14: True Health Actions Create a Personalized Digital Experience
True Health Actions Create a Personalized Digital Experience Accolade Driven user need “For you” Support call(s) to action (True Health Actions) Member Driven user need “Ways we can help” Bring User Need resolution paths to front 14 Accolade ©2024 - Confidential
Slide 15: What AI means at Accolade
Artificial Intelligence A program and capabilities that can sense, reason, act, and adapt Machine Learning What AI means Algorithms whose performance improve as they are exposed to more data over time at Accolade Data Platform Foundational multi-layered data architecture that is the proprietary sour
Slide 16: Our AI capabilities and utilization
Our AI capabilities and utilization § Interaction Monitoring § Population Health § Clinical Analytics § Auto QA Evaluations § Clinical Foundation Score § Workforce Management Forecasting § Auto Note Summarization § EMO ML Models § NPS and CSAT Sentiment § Conversational AI across IVR § Decision & Wo
Slide 17: Accolade's Advantages for the Healthcare Ecosystem
Accolade’s Advantages for the Healthcare Ecosystem Front Line Care Teams Data set End to end reporting 17 Accolade ©2024 - Confidential
Slide 18: Trusted Partner Ecosystem
Trusted Partner Ecosystem High-quality solutions, complementary to Accolade’s own services, in categories that matter to our customers Musculoskeletal Diabetes / Metabolic Pharmacy Centers of Excellence Behavioral Health Health Equity [object File] Gastrointestinal Fertility Healthcare Wellness / In
Slide 19: Driving appropriate use of customers' programs is core to our value proposition
Driving appropriate use of customers’ programs is core to our value proposition Ecosystem Programs Trusted Partner Ecosystem Existing point solutions Best-in-class solutions where customers enjoy easier purchasing and + implementation, enhanced features, and incremental utilization Benefit Warm site
Slide 20: Business Model Builds Momentum as Adoption Grows
Engage Partner Identify Business Model Builds Momentum as Adoption Grows Expert Route MD Primary Care 20 Accolade ©2024 - Confidential
Slide 21: Distribution Reach
Distribution Reach 21 Accolade ©2024 - Confidential
Slide 22: Diversified customer profiles create opportunity and expand TAM
Diversified customer profiles create opportunity and expand TAM • Diversified across • Size • Industry • Enterprise, government, Broad customer health plan, consumer profile • Direct • Health Plan • Integrated • Consumer Multi-offering • Ecosystem Partners Diversified • Leverage investments platform
Slide 23: Business Model Builds Momentum as Adoption Grows
Business Model Builds Momentum as Adoption Grows Early and Repeat Expert Physicians Engagement Diagnosis & Treatment Review Member Insights and care recommendation 69% PCPs & Therapists Acute, Chronic & Preventive Ongoing data analysis Care team interaction and influence Registered Member Nurses Car
Slide 24: Improved Outcomes Across Conditions
Improved Outcomes Across Conditions No True One or more True Improvement Health Action Health Action Musculoskeletal AVOIDABLE ER VISITS 57% members engaged 44% received 1+ Interventions 15% 13% -13% Depression or Anxiety OUTPATIENT BH VISITS (per member per year) 47% members engaged 35% received 1+
Slide 25: Financials
Financials
Slide 26: Accelerating Accolade's Innovation
Accelerating Accolade’s Innovation Continuous investment in clinical transformation and operational excellence Created a Proven Launched Intelligent Launched Launched Mental Acquired 2nd.MD - Acquired PlushCare - Introduced High Touch, High Provider Matching Accolade COVID Health Integrated Expert M
Slide 27: Significantly Expanded Addressable Market
Significantly Expanded Addressable Market $216 billion TAM 900 Customers 800+ $170B 800 Primary Care 700 600+ 600 500 $22B 400 Expert Medical Opinion 300 200 $24B 112 Navigation & Advocacy 100 54 15 20 0 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 (w M&A) 27 Accolade ©2024 - Confidential
Slide 28: Consistent growth and progress toward profitability
Consistent growth and progress toward profitability Revenue R ~$413M 33% CAG $363M $310M $170M $133M FY20 FY21 FY22 FY23 FY24P Adjusted EBITDA (Loss) & Adjusted OpEx as % of revenue 70% 61% 60% 57% ~50% -16% -14% -10% -25% -2% FY20 FY21 FY22 FY23 FY24P 28 FYE = February
Slide 29: Strong visibility to growth and profitability
Strong visibility to growth and profitability Targeting $1 billion revenue and 15-20% Adjusted EBITDA in FY29 Revenue AEBITDA $1B+ Horizon 2 Key drivers • Integrated healthcare platform Horizon 1 G R o Advocacy CA o Primary Care and mental health 0% 2 o Expert Medical Opinion ~$500M o Trusted Partne
Slide 30: Customer and revenue diversification
Customer and revenue diversification FY23 800+ customers FY20 § 200+ Advocacy § 600+ EMO § Launched eVPC in past year § >10% with >1 core offering § No 5% customer in FY24P § Broad industry diversification § 54 customers § 6 customers ~ 75% of revenue 30 Accolade ©2024 - Confidential
Slide 31: Financial Targets and Goals (Non-GAAP)
Long-Term Goals Adj. Gross Margin 50-55% P&T as 13-17% Financial Targets % of Rev. and Goals Adj. S&M as Operating 15-20% (Non-GAAP) Expenses % of Rev. G&A as 7-9% % of Rev. Adj. EBITDA Margin 15-20% 31 Accolade ©2024 - Confidential
Slide 32: Growth, Scale & Profitability
Growth, Scale & Profitability Highly diversified revenue mix Expanding margins and operating leverage One Accolade driving operational efficiencies Attractive and improving unit economics Clear vision toward $1B+ revenue and target financial model Accolade ©2023 32
Slide 33: Accolade Personalized Healthcare
Accolade PERSONALIZED HEALTHCARE
Slide 34: Appendix
Appendix 34
Slide 35: Reconciliations of Revenue to Adjusted Gross Profit & Net loss to Adjusted EBITDA
Reconciliations of Revenue to Adjusted Gross Profit & Net loss to Adjusted EBITDA Adjusted Gross Profit is a non-GAAP financial measure that we define as revenue less cost of revenue, excluding depreciation and amortization, and excluding stock-based compensation and severance costs. We define Adjus
Slide 36: Adjusted EBITDA (Loss) Reconciliation
Adjusted EBITDA (Loss) Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2020 2021 2022 2023 Net Loss $ (51,365) $ (50,652) $ (123,124) $ (459,650) Adjusted for: Interest expense (income), net 2,925 3,724 2,905 (255) Income tax expense (benefit) 129 4 (5,639) (3,624) Depreciation a
Slide 37: Adjusted Gross Margin Reconciliation
Adjusted Gross Margin Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2020 2021 2022 2023 Revenue $ 132,507 $ 170,358 $ 310,021 $ 363,142 Less: Cost of revenue, excluding depreciation and (73,685) (93,673) (169,019) (198,905) amortization Gross Profit, excluding depreciation and
Slide 38: Adjusted Operating Expense Reconciliation
Adjusted Operating Expense Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2020 2021 2022 2023 Revenue $ 132,507 $ 170,358 $ 310,021 $ 363,142 Operating Expenses 107,026 123,462 266,727 627,751 Less: Depreciation and amortization (8,516) (8,212) (42,608) (46,377) Stock-based comp
Slide 39: Accolade Personalized Healthcare
Accolade PERSONALIZED HEALTHCARE